For decades, the Environmental Protection Agency’s list of drinking water contaminants has focused on the usual suspects: lead, arsenic, bacteria, industrial solvents. The kind of pollutants you’d expect to find downstream from a factory or leaching from aging pipes. But on March 31, the agency took a step that signals a fundamental expansion of what the federal government considers a threat in the nation’s water supply.
Microplastics. Pharmaceuticals. Per- and polyfluoroalkyl substances. Manganese.
The EPA added all of them to its fifth Contaminant Candidate List, known as CCL-5 — a regulatory watchlist of unregulated substances that may require future drinking water standards. The list now contains 30 individual contaminants and three broad contaminant groups, a significant expansion from previous iterations. It doesn’t mean new regulations are imminent. But it puts the water industry, municipal utilities, and chemical manufacturers on notice that the regulatory ground is shifting beneath them.
As reported by Slashdot, the inclusion of microplastics marks the first time the EPA has formally flagged them as a potential drinking water contaminant at the federal level. That alone is significant. Microplastics — tiny fragments of plastic less than five millimeters in diameter — have been found in virtually every water source tested, from municipal tap water to bottled water to remote mountain streams. Their health effects in humans remain under active investigation, but animal studies have linked exposure to inflammation, endocrine disruption, and cellular damage.
The CCL is not a regulation. It’s a precursor to one. Under the Safe Drinking Water Act, the EPA is required to periodically publish a list of contaminants that are not currently subject to national primary drinking water regulations but are known or anticipated to occur in public water systems. From this list, the agency must decide whether to regulate at least five contaminants. The process is slow — often spanning a decade or more from listing to enforceable standard — but inclusion on the CCL is the essential first step.
What’s Actually on the List — and Why It Matters Now
The 30 contaminants and three groups on CCL-5 represent a broad cross-section of emerging concerns. PFAS, the so-called “forever chemicals” used in nonstick coatings, firefighting foam, and food packaging, appear as a class. The EPA has already finalized drinking water limits for six individual PFAS compounds under a separate rulemaking, but the CCL-5 listing of the broader PFAS group suggests the agency is eyeing the thousands of other PFAS variants that escaped that initial rule.
Pharmaceuticals on the list include common medications that enter the water supply through human excretion, improper disposal, and agricultural runoff. Antibiotics, hormones, and antidepressants have been detected in water systems across the country for years. Water treatment plants were never designed to remove them. Most still don’t.
Manganese is a somewhat different case. It’s a naturally occurring mineral that, at elevated levels, has been associated with neurological effects, particularly in children. Several states already have their own manganese guidelines, but there’s no federal standard. Its inclusion on CCL-5 could change that.
And then there are microplastics. The science here is evolving fast. A widely cited 2024 study published in the Proceedings of the National Academy of Sciences found nanoplastics and microplastics in bottled water at concentrations far higher than previously estimated — roughly 240,000 plastic fragments per liter. Researchers at Columbia University used a novel laser-based imaging technique to detect particles previously invisible to standard methods. The health implications are still being mapped, but the sheer ubiquity of exposure has pushed regulators to act.
California moved first. In 2020, the state became the first in the nation to mandate microplastic testing in drinking water, with the State Water Resources Control Board developing standardized methods for detection. The EPA’s CCL-5 listing could eventually lead to a similar requirement at the national level.
The Industry Response: Uncertainty, Cost, and Opportunity
For the roughly 50,000 community water systems in the United States, the CCL-5 additions raise immediate practical questions. How do you test for microplastics when standardized federal methods don’t yet exist? What treatment technologies can remove pharmaceutical residues at scale? And who pays?
The American Water Works Association, the industry’s primary trade group, has historically supported science-based regulation but has also warned against moving faster than the science warrants. Treatment upgrades are expensive. Advanced oxidation processes, granular activated carbon filtration, and reverse osmosis systems can address many of the contaminants on the new list, but retrofitting aging infrastructure to deploy them would cost billions. Small and rural water systems, which serve roughly 20% of the U.S. population, are particularly vulnerable. They often lack the engineering staff and financial reserves to respond to new mandates.
The financial stakes are real. The EPA’s own 2023 Drinking Water Infrastructure Needs Survey estimated that the nation’s water systems require $625 billion in investment over the next 20 years just to maintain current service levels. Adding new contaminant standards on top of that figure would push the total higher — potentially much higher.
But where utilities see cost, technology companies see a market. The global water treatment chemicals market was valued at approximately $38 billion in 2023 and is projected to grow steadily as regulatory requirements tighten worldwide. Companies specializing in advanced filtration, membrane technology, and real-time water quality monitoring stand to benefit directly from the kind of regulatory expansion the CCL-5 represents. Firms like Xylem, Veolia, and Evoqua (now part of Xylem after a 2023 merger) have already positioned themselves for this shift.
Private equity has noticed too. Investment in water technology startups has accelerated over the past three years, driven partly by PFAS litigation, partly by climate-related water stress, and partly by the expectation that federal regulation will eventually force upgrades that municipalities can’t fund alone.
So the CCL-5 is more than a list. It’s a signal — to investors, to utilities, to chemical manufacturers, and to the public — about where federal water policy is headed.
The political dimension can’t be ignored. The EPA under the current administration has faced pressure from both sides: environmental groups demanding faster action on emerging contaminants, and industry groups arguing that premature regulation based on incomplete science could divert resources from known, quantifiable risks. The CCL process is designed to thread that needle, but it satisfies almost no one fully. Environmentalists point out that contaminants can sit on the list for years without any regulatory action. Industry representatives worry that inclusion on the list creates de facto pressure to regulate even before the science is settled.
There’s also the matter of enforcement. Even when the EPA does set a drinking water standard, compliance depends on monitoring, reporting, and state-level enforcement — all of which vary enormously across jurisdictions. The agency finalized PFAS limits in April 2024, setting maximum contaminant levels for six PFAS compounds at four parts per trillion — an extraordinarily low threshold. Water systems have until 2029 to comply. Whether they will, and whether states will enforce those limits aggressively, remains an open question.
What Comes Next
The CCL-5 triggers a specific regulatory sequence. The EPA must now conduct a Regulatory Determination process, evaluating the listed contaminants against three criteria: the contaminant may have adverse health effects, it occurs or is substantially likely to occur in public water systems with a frequency and at levels of public health concern, and regulation presents a meaningful opportunity to reduce health risk. If a contaminant meets all three, the agency is obligated to propose a national standard.
For microplastics, that determination could take years. The science is advancing rapidly, but fundamental questions remain unanswered. What size particles matter most? What concentrations pose genuine health risks? Are certain types of plastic — polyethylene terephthalate versus polypropylene, for instance — more dangerous than others? Without answers, setting a defensible standard is difficult.
Pharmaceuticals present a different challenge. The compounds are diverse, their health effects at trace concentrations are poorly understood, and the sources are diffuse. Regulating them in drinking water could eventually force changes not just at water treatment plants but upstream — in pharmaceutical manufacturing, hospital waste disposal, and agricultural practices.
PFAS regulation, meanwhile, is already further along than anything else on the CCL-5, but the class-based listing signals that the EPA isn’t done. The six compounds covered by the 2024 rule represent a fraction of the PFAS universe. Industry estimates suggest there are more than 12,000 individual PFAS chemicals in commerce. Regulating them as a class, rather than one by one, has been a longstanding demand of environmental advocates and a persistent concern for chemical manufacturers, who argue that not all PFAS pose equal risk.
The water industry is watching all of this with a mix of resignation and urgency. The contaminants on the CCL-5 aren’t new discoveries. Water utility professionals have been tracking microplastics, pharmaceuticals, and PFAS for years. What’s new is the federal government formally acknowledging these substances as potential drinking water threats — a step that, however incremental, sets the regulatory clock ticking.
For consumers, the practical takeaway is nuanced. The presence of these contaminants on a watchlist doesn’t mean tap water is unsafe today. It means the government is beginning the long process of deciding whether to set limits on substances that weren’t contemplated when the Safe Drinking Water Act was last significantly updated. The gap between what’s in the water and what’s regulated has been widening for years. The CCL-5 is an attempt — a slow, bureaucratic, but consequential attempt — to close it.
The real test will be whether the regulatory process can keep pace with the science. History suggests it can’t. But the inclusion of microplastics and pharmaceuticals on a federal contaminant list for the first time represents a shift in posture, if not yet in policy. The water industry, and the communities it serves, will be living with the consequences of that shift for decades to come.
WebProNews is an iEntry Publication